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This study screened large cohorts of node-positive and node-negative breast cancer patients to determine whether the G388R
mutation of the FGFR4 gene is a useful prognostic marker for breast cancer as reported by Bange et al in 2002. Node-positive
(n¼139) and node-negative (n¼95) breast cancer cohorts selected for mutation screening were followed up for median periods of
89 and 87 months, respectively. PCR – RFLP analysis was modified to facilitate molecular screening. Curves for disease-free survival
were plotted according to the Kaplan – Meier method, and a log-rank test was used for comparisons between groups. Three other
nonparametric linear rank-tests particularly suitable for investigating possible relations between G388R mutation and early cancer
progression were also used. Kaplan – Meier analysis based on any of the four nonparametric linear rank tests performed for node-
positive and node-negative patients was not indicative of disease-free survival time. G388R mutation of the FGFR4 gene is not
relevant for breast cancer prognosis.
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Many components of mitogenic signalling pathways have been
identified over the past 15 years, including the large family of
protein kinases. Dysregulation of these biological processes
may play an important role in the growth and survival of
cancer cells. The 20 members of the fibroblast growth factor
(FGF) family transduce a variety of biological signals via distinct
transmembrane tyrosine kinase receptors (FGFR1 – FGFR4)
encoded by four closely related genes (Powers et al, 2000). Mature
FGFR proteins, which act as membrane-spanning tyrosine kinase
receptors, have an extracellular ligand-binding domain, a trans-
membrane domain and a split intracellular tyrosine kinase domain
(Green et al, 1996). Fibroblast growth factor -mediated signals
have mitogenic, angiogenic and hormone regulatory effects and
play key roles in a wide variety of crucial biological activities
requiring cell growth, differentiation, migration and chemotaxis.
Molecular anomalies of FGFR genes (inappropriate expression,
single nucleotide polymorphism (SNP), splice variations, genomic
alterations) have been described in several types of human
cancer (bladder, cervical, colorectal carcinomas and multiple
myeloma) and in skeletal deformities (achondroplasia, Crouzon
syndrome and thanatophoric dysplasia type II) (Muenke and
Schell, 1995; Avet-Loiseau et al, 1998; Cappellen et al, 1999; Vajo
et al, 2000. Bange et al, (2002) recently studied the role of an SNP
responsible for a missense mutation (G388R) in the transmem-
brane domain of FGFR4, in the progression and prognosis of
nodepositive breast cancer. This G-A transition changes the
sense of codon 388 from Gly (GGG) to Arg (AGG). The authors
concluded that the G388R mutation in heterozygous or homo-
zygous state was significantly over-represented in node-positive
breast cancer patients with early relapse, but has no role in tumour
formation, making this SNP a prognostic marker. On a worldwide
basis, they found that allele distribution in normal controls and
breast cancer patients did not differ significantly, showing an
estimated 45.4% for the Gly/Gly allele, 45.7% for the Gly/Arg allele,
and 8.9% for the Arg/Arg allele (Bange et al, 2002). No relationship
has been found between this SNP and the prognosis for node-
negative breast cancer.
Our aim was to confirm the findings of Bange et al on a
larger cohort, using an improved PCR – RFLP analysis and a
reinforced and more adapted statistical analysis for investigating
the possible association between G388R mutation and early cancer
progression. Screening was conducted in a cohort of node-positive
breast cancer patients who received different adjuvant therapies
(endocrine (n¼67), or chemotherapeutic (n¼72)) and in a cohort
of node-negative breast cancer patients (n¼95). These cohorts
were followed up, respectively, for median periods of 89 and 87
months. PCR – RFLP analysis was modified to make molecular
screening more convenient and less time-consuming. Curves
for disease-free survival (DFS) were plotted according to the
Kaplan – Meier method, and the log-rank test was used for
comparisons between groups, as in the study of Bange et al,
(Kaplan and Meier, 1958; Cox and Oakes, 1984). Statistical analysis
was reinforced by using three other nonparametric linear rank
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ytests (Breslow, Peto – Prentice and Tarone – Ware) (Breslow, 1970;
Peto and Peto, 1972; Tarone and Ware, 1977; Prentice, 1978).
MATERIALS AND METHODS
Patients
The study included 234 consecutive unselected women with
primary breast tumours, who were diagnosed and treated
primarily between 1988 and 1997 at the Rene ´ Gauducheau Cancer
Center. Informed consent was obtained from patients to use their
surgical specimens and clinicopathological data for research
purposes, as required by the French Committee for the Protection
of Human Subjects. These patients showed no evidence of distant
metastasis at the time of diagnosis. None had received chemother-
apy, endocrine therapy or radiation therapy prior to surgery.
Treatment decisions were based solely on consensus recommenda-
tions at the time of diagnosis. Patients were followed up for DFS
(delimited by the first clinically recognised evidence of local or
distant recurrence). Node-positive cohort was composed of 139
patients (mean age 55.4 years, range 32–80), who received
different adjuvant therapies (tamoxifen, n¼67; 5-fluorouracil
(500mg/m
 2), epirubicin (50mg/m
 2) and cyclophosphamide
(500mg/m
 2) (FEC50), n¼72) after primary surgery and post-
operative radiation therapy. Node-positive patients were followed
up every 4 months during 2 years, then every 6 months during 3
years, and annually thereafter. Clinical examination, mammogra-
phy and chest radiography were performed twice a year, and bone
scintigraphy and liver ultrasonography annually. The node-
negative cohort was composed of 95 patients (mean age 57.1
years, range 34–78), all of whom were treated only by primary
surgery and postoperative radiation therapy (median follow-up 87
months, range 58–164). The follow-up of node-negative patients
included clinical examination, mammography and chest radio-
graphy every 6 months during 2 years and annually thereafter. The
clinicopathologic characteristics of the patients are indicated in
Table 1.
DNA samples
All tumour tissue samples were surgically collected, typed by a
pathologist and grossly dissected before being snap-frozen in
liquid nitrogen. To exclude the presence of ‘contaminating’ cancer-
associated somatic mutations affecting the locus of interest or loss
of heterozygosity, 70 randomly selected patients were screened
both in tumour tissue and in peripheral white blood cells (WBCs).
Peripheral venous blood samples were taken just before breast
resection or mastectomy. DNA was isolated according to standard
protocols from peripheral WBCs and from shock-frozen grossly
dissected breast cancer tissues.
PCR – RFLP analysis
The primers described by Bange et al were applied to screen for
G388R mutation, but with the following modifications: PCR-
mediated site-directed mutagenesis used the PCR forward primer
with a single base mismatch (C-A: in bold type) to destroy a
constant BstNI restriction site that complicated visualisation of the
restriction profile of the corresponding PCR product, and a
guanine was added to the 30 end of this primer to improve
annealing (50 GACCGCAGCAGCGCCCGAGGCAAGG 30). In the
reverse primer, an adenine was turned into a cytosine (in bold
type), according to the GenBank sequence (accession number:
Y13901) (50 AGAGGGAAGCGGGAGAGCTTCTG 30). Under these
conditions, the undigested PCR product had a length of 168bp.
The G-A transition in codon 388 created a new BstNI restriction
site (CCkWGG). As a positive control for the digestion efficiency
of BstNI, an additional BstNI restriction site was located in the
168bp PCR product.
Reactions were performed with 500ng of genomic DNA in a total
volume of 50ml containing (final concentration) 10mM Tris-HCl
(pH 8.3), 50mM KCl, 2.5mM MgCl2, 0.25mM of the four
deoxynucleotide triphosphates, 1U of Taq polymerase (Applied
Biosystems, Branchburg, NJ, USA) and 0.25mM of each primer. PCR
conditions were as follows: preliminary denaturation at 951Cf o r
5min, followed by 35 cycles of 30s at 951C and 45s at 721C. The
reaction terminated with 5min at 721C. The digestion reactions
contained 10ml of PCR product, 0.5mlo fBstNI (5U; New England
Biolabs, Beverly, MA, USA), 2mlo f1 0  NEBuffer 2 (supplied with
the enzyme) and 0.2ml bovine serum albumin (100mgl
 1) in a final
volume of 20ml. These components were incubated for 60min at
601C. After the reaction ended, 10ml of the PCR mixture were
mixed with a loading buffer and electrophoresed in a 4% agarose
1000
s gel (Life Technologies, Carlsbad, CA, USA). Bands were
visualised by ethidium bromide staining of the gel.
Statistical methods
The variable of interest was DFS, and survival curves for DFS were
plotted according to the Kaplan – Meier method. Comparison
Table 1 Clinicopathologic characteristics of the two cohorts
N+ N 
No. of patients 139 95
Mean age at diagnosis (years) 55.4 57.1
Median follow-up (months) 89 87
Relapse 57 25
Primary surgery 139 95
Adjuvant radiation therapy 139 95
Adjuvant endocrine therapy (Tam) 67 0
Adjuvant chemotherapy (FEC50) 72 0
Histological type
Infiltrating ductal carcinoma 121 70
Infiltrating lobular carcinoma 8 11
Others 10 14
No. of positive axillary lymph nodes
00 9 5
1 – 3 109 0
433 0 0
Tumor size (mm)
o 20 27 51
X20 99 41
Not determined 13 3
Elston Ellis histological grade
I9 3 0
II 68 48
III 45 4
Not determined 17 13
Hormone receptor status
ER+/PgR+ 88 67
ER /PgR+ 13 3
ER+/PgR- 26 12
ER /PgR- 19 12
Not determined 3 1
Relapse site
Local only 14 11
Any distant site 43 14
N ¼ node-negative; N+¼ node-positive, Tam¼ tamoxifen; ER¼oestrogen
receptor, PgR¼ progesterone receptor.
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test, as in the study of Bange et al, and three other non-parametric
linear rank tests were added (Breslow, Tarone – Ware and Peto –
Prentice). These four tests used to assess the equality of the
survivor function across groups are members of a family of
statistical tests that serve as extensions to the censored data of
traditional nonparametric rank tests for comparison of two or
more distributions. Quite simply, the contribution to the statistical
test is obtained at each distinct relapse time in the data as a
weighted standardised sum of differences between the observed
and expected number of events in each of the K groups. The
expected number of events is obtained under the null hypothesis of
no differences in the global survival experience of the K groups.
The weight function used determines the statistical test: 1 for the
log-rank test, ni (number of subjects in the risk pool at each
relapse time i) for the Breslow test, ni1/2 for the Tarone – Ware test,
and S(ti) (estimated Kaplan – Meier survivor fraction value at each
relapse time i) for the Peto – Prentice test. The earlier the relapse
time, the greater the weight. Thus, these tests are quite suited for
investigating the possible relation between G388R mutation and
early cancer progression. All tests were performed at a significance
level of a¼0.05. Two groups were followed, as in the study of
Bange et al: Gly/Gly alleles and Gly/Arg alleles plus Arg/Arg alleles.
Analyses were performed using the BMDP statistical software
(Dixon, 1981).
RESULTS
PCR – RFLP analysis
After digestion with BstNI, the wild-type allele produced two
fragments of 109 and 59bp. Conversely, the PCR product
containing the G-A transition in heterozygous state produced
four fragments of 109, 80, 59 and 29bp. The homozygous state
produced three fragments of 80, 59 and 29bp. The 29-bp fragment
was not visible on agarose gel (Figure 1).
Germinal mutation
The same genotype was found in 70 tumour tissues and
corresponding peripheral WBCs, which proved the germinal origin
of the G388R mutation.
Allele distribution
Allele distribution of the G388R mutation in our local breast
cancer population showed 51.7% of patients with homozygous Gly/
Gly alleles, 37.2% with heterozygous Gly/Arg alleles, and 11.1%
with homozygous Arg/Arg alleles. Allele distribution frequency
between node-positive and node-negative patients was not
significantly different (w
2¼0.38; P¼0.827; data not shown). The
results of G388R mutation screening are summarised in Table 2.
Allele distribution frequency between our patients and the groups
studied by Bange et al was not significantly different (w
2¼4.3;
P¼0.12; data not shown). The G388R mutation appears to be as
widespread in non-Caucasian (Chinese) as Caucasian populations
(Bange et al, 2002).
Usefulness of the FGFR4 genotype as a breast cancer
prognostic marker
As shown in Table 3, no correlation was observed between the
FGFR4 allele and pathological parameters such as age at diagnosis,
tumour size, Elston Ellis histological grade and hormone receptor
status in node-postive and in node-negative patients.  ← 168 bp 
 ← 109 bp 
 ←  80  bp 
 ←  59  bp 
1 2 3 4 5
Figure 1 PCR – RFLP analysis of FGFR4 gene G388R mutation. Lane 1,
HaeIII-digested pBR322 size marker; lane 2, amplification control; lane 3,
wild-type control (Gly/Gly), BstNI – digested; lane 4, heterozygote carrier
(Gly/Arg), BstNI – digested; lane 5, homozygote carrier (Arg/Arg), BstNI –
digested.
Table 2 FGFR4 G388R allele distribution in the two breast cancer
cohorts
Gly/Gly Gly/Arg Arg/Arg
nn% n% n%
N+ 139 73 52.5 52 37.4 14 10.1
N  95 48 50.5 35 36.9 12 12.6
Table 3 Association between FGFR4 alleles and pathological parameters
N+ N 
Arg/Arg Gly/Arg Gly/Gly P Arg/Arg Gly/Arg Gly/Gly P
Age at diagnosis (years) 55.9 (12.5)
a 54.9 (11.4) 0.64 56.1 (11.7) 58.1 (11.2) 0.41
Tumour size (mm) 27.6 (12.9) 30.7 (17.7) 0.27 17.6 (6.7) 19.2 (10.4) 0.38
Elston Ellis histological grade
I3 6 1 3 1 7
II 34 34 0.64 25 23 0.75
III 22 23 2 2
Hormone receptor status
ER+/PgR+ 43 45 33 34
ER-/PgR+ 4 6 0.93 3 0 0.34
ER+/PgR  10 9 6 6
ER-/PgR  91 0 5 7
N ¼node-negative, N+¼ node-positive, ER¼ oestrogen receptor, PgR¼ progesteron receptor.
aMean (s.d.).
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metric linear rank tests, when performed for node-positive
patients, did not show any statistically significant difference in
DFS according to G388R status, which is contrary to the findings of
Bange et al (Figure 2). The P-values of the different tests are
indicated in Table 4. Power calculation strengthened our negative
results for node-positive patients (1 b¼0.92) (Freedman, 1982).
As Bange et al showed, no relation for survival was found between
DFS time and G388R status in node-negative patients.
Discussion
In conclusion, the G388R mutation of the FGFR4 gene does not
appear to be an effective prognostic marker of breast cancer,
contrary to the findings of Bange et al. Larger patient cohorts (139
vs 46 node-positive patients) and powerful statistical methods
(Breslow, Tarone – Ware or Peto – Prenctice) were used in the
present study, but no statistically significant difference in DFS
according to G388R status was detected during early follow-up.
Since complete clinicopathologic characteritics from Bange et al
cohorts are not available, such as age at diagnosis, tumour size,
histological grade, pN and hormone receptor status, we cannot
exclude a possible link between one of these pathological
parameters and the G388R mutation, which could create some
confounding in the survival analysis.
Recent studies have focused on the possible implication of
FGFR4 in the carcinogenesis of different cancers (Coope et al,
1997; Olson et al, 1998; Hart et al, 2000; Cavallaro et al, 2001; La
Rosa et al, 2001; Ezzat et al, 2002; Shah et al, 2002). All these
results indicate the complexity of the FGFR4 signalling pathway
and the weak frontier separating normal from malignant cell
proliferation. The role of FGFR4 in carcinogenesis is still under
investigation, notably the relation between genotype and pheno-
type, but also its involvement in cancer progression via paracrine/
autocrine modulation of FGFR4 ligands and FGFR4 and its
possible implication in an oncogenic multistep process, as
described for FGFR3 in multiple myeloma (Chesi et al, 2001).
However, further studies are needed to explore the role of this
mutation as a molecular marker and the possible value of the
FGFR4 gene or protein as a target for cancer therapy.
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